nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—Blood pressure systolic increased—Sorafenib—liver cancer	0.0976	0.114	CcSEcCtD
Travoprost—Dinoprost Tromethamine—HPGDS—liver cancer	0.0381	1	CrCbGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA4—liver cancer	0.0324	0.297	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA5—liver cancer	0.0186	0.17	CbGpPWpGaD
Travoprost—Dysphonia—Sorafenib—liver cancer	0.0172	0.0202	CcSEcCtD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA2—liver cancer	0.017	0.156	CbGpPWpGaD
Travoprost—Bone disorder—Sorafenib—liver cancer	0.0157	0.0184	CcSEcCtD
Travoprost—Blood pressure increased—Sorafenib—liver cancer	0.0142	0.0166	CcSEcCtD
Travoprost—Drug hypersensitivity—Epirubicin—liver cancer	0.013	0.0152	CcSEcCtD
Travoprost—Prostatic disorder—Epirubicin—liver cancer	0.0123	0.0144	CcSEcCtD
Travoprost—Drug hypersensitivity—Doxorubicin—liver cancer	0.012	0.0141	CcSEcCtD
Travoprost—Prostatic disorder—Doxorubicin—liver cancer	0.0114	0.0134	CcSEcCtD
Travoprost—Lacrimation—Epirubicin—liver cancer	0.0089	0.0104	CcSEcCtD
Travoprost—Skin hyperpigmentation—Epirubicin—liver cancer	0.0088	0.0103	CcSEcCtD
Travoprost—Lacrimation—Doxorubicin—liver cancer	0.00824	0.00966	CcSEcCtD
Travoprost—Skin hyperpigmentation—Doxorubicin—liver cancer	0.00814	0.00955	CcSEcCtD
Travoprost—Keratitis—Epirubicin—liver cancer	0.00807	0.00947	CcSEcCtD
Travoprost—Infestation NOS—Sorafenib—liver cancer	0.00792	0.00929	CcSEcCtD
Travoprost—Infestation—Sorafenib—liver cancer	0.00792	0.00929	CcSEcCtD
Travoprost—Keratitis—Doxorubicin—liver cancer	0.00747	0.00876	CcSEcCtD
Travoprost—Dermatitis atopic—Epirubicin—liver cancer	0.00707	0.00829	CcSEcCtD
Travoprost—Urinary tract disorder—Sorafenib—liver cancer	0.00702	0.00824	CcSEcCtD
Travoprost—Connective tissue disorder—Sorafenib—liver cancer	0.00699	0.0082	CcSEcCtD
Travoprost—Urethral disorder—Sorafenib—liver cancer	0.00697	0.00818	CcSEcCtD
Travoprost—Scotoma—Epirubicin—liver cancer	0.00689	0.00808	CcSEcCtD
Travoprost—Tinnitus—Sorafenib—liver cancer	0.00663	0.00778	CcSEcCtD
Travoprost—Cardiac disorder—Sorafenib—liver cancer	0.0066	0.00774	CcSEcCtD
Travoprost—Dermatitis atopic—Doxorubicin—liver cancer	0.00654	0.00767	CcSEcCtD
Travoprost—Angiopathy—Sorafenib—liver cancer	0.00645	0.00757	CcSEcCtD
Travoprost—Immune system disorder—Sorafenib—liver cancer	0.00642	0.00754	CcSEcCtD
Travoprost—Mediastinal disorder—Sorafenib—liver cancer	0.00641	0.00752	CcSEcCtD
Travoprost—Scotoma—Doxorubicin—liver cancer	0.00638	0.00748	CcSEcCtD
Travoprost—Dysphonia—Epirubicin—liver cancer	0.00636	0.00746	CcSEcCtD
Travoprost—Mental disorder—Sorafenib—liver cancer	0.00623	0.00731	CcSEcCtD
Travoprost—Erythema—Sorafenib—liver cancer	0.00619	0.00726	CcSEcCtD
Travoprost—Dysgeusia—Sorafenib—liver cancer	0.00606	0.00711	CcSEcCtD
Travoprost—Dysphonia—Doxorubicin—liver cancer	0.00589	0.0069	CcSEcCtD
Travoprost—Bone disorder—Epirubicin—liver cancer	0.0058	0.0068	CcSEcCtD
Travoprost—Skin discolouration—Epirubicin—liver cancer	0.0058	0.0068	CcSEcCtD
Travoprost—Herpes simplex—Epirubicin—liver cancer	0.00568	0.00666	CcSEcCtD
Travoprost—Lacrimation increased—Epirubicin—liver cancer	0.00568	0.00666	CcSEcCtD
Travoprost—Cough—Sorafenib—liver cancer	0.0054	0.00634	CcSEcCtD
Travoprost—Inflammation—Epirubicin—liver cancer	0.0054	0.00633	CcSEcCtD
Travoprost—Skin discolouration—Doxorubicin—liver cancer	0.00536	0.00629	CcSEcCtD
Travoprost—Bone disorder—Doxorubicin—liver cancer	0.00536	0.00629	CcSEcCtD
Travoprost—Hypertension—Sorafenib—liver cancer	0.00535	0.00627	CcSEcCtD
Travoprost—Musculoskeletal pain—Epirubicin—liver cancer	0.0053	0.00621	CcSEcCtD
Travoprost—Myalgia—Sorafenib—liver cancer	0.00527	0.00618	CcSEcCtD
Travoprost—Arthralgia—Sorafenib—liver cancer	0.00527	0.00618	CcSEcCtD
Travoprost—Herpes simplex—Doxorubicin—liver cancer	0.00526	0.00616	CcSEcCtD
Travoprost—Lacrimation increased—Doxorubicin—liver cancer	0.00526	0.00616	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00524	0.00614	CcSEcCtD
Travoprost—Dermatitis contact—Epirubicin—liver cancer	0.00517	0.00607	CcSEcCtD
Travoprost—Dry mouth—Sorafenib—liver cancer	0.00516	0.00605	CcSEcCtD
Travoprost—Infection—Sorafenib—liver cancer	0.00502	0.00589	CcSEcCtD
Travoprost—Inflammation—Doxorubicin—liver cancer	0.00499	0.00586	CcSEcCtD
Travoprost—Nervous system disorder—Sorafenib—liver cancer	0.00496	0.00581	CcSEcCtD
Travoprost—Skin disorder—Sorafenib—liver cancer	0.00491	0.00576	CcSEcCtD
Travoprost—Musculoskeletal pain—Doxorubicin—liver cancer	0.0049	0.00575	CcSEcCtD
Travoprost—Dry eye—Epirubicin—liver cancer	0.00483	0.00567	CcSEcCtD
Travoprost—Dermatitis contact—Doxorubicin—liver cancer	0.00479	0.00561	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0046	0.0054	CcSEcCtD
Travoprost—Abnormal vision—Epirubicin—liver cancer	0.00457	0.00535	CcSEcCtD
Travoprost—Dyspnoea—Sorafenib—liver cancer	0.00451	0.00528	CcSEcCtD
Travoprost—Dry eye—Doxorubicin—liver cancer	0.00447	0.00525	CcSEcCtD
Travoprost—Dyspepsia—Sorafenib—liver cancer	0.00445	0.00522	CcSEcCtD
Travoprost—Gastrointestinal disorder—Sorafenib—liver cancer	0.00436	0.00512	CcSEcCtD
Travoprost—Fatigue—Sorafenib—liver cancer	0.00436	0.00511	CcSEcCtD
Travoprost—Pain—Sorafenib—liver cancer	0.00432	0.00507	CcSEcCtD
Travoprost—Constipation—Sorafenib—liver cancer	0.00432	0.00507	CcSEcCtD
Travoprost—Abnormal vision—Doxorubicin—liver cancer	0.00422	0.00495	CcSEcCtD
Travoprost—Eye pain—Epirubicin—liver cancer	0.00421	0.00494	CcSEcCtD
Travoprost—Gastrointestinal pain—Sorafenib—liver cancer	0.00413	0.00485	CcSEcCtD
Travoprost—Abdominal pain—Sorafenib—liver cancer	0.00399	0.00469	CcSEcCtD
Travoprost—Eye pain—Doxorubicin—liver cancer	0.00389	0.00457	CcSEcCtD
Travoprost—Hypersensitivity—Sorafenib—liver cancer	0.00372	0.00437	CcSEcCtD
Travoprost—Asthenia—Sorafenib—liver cancer	0.00363	0.00425	CcSEcCtD
Travoprost—Pruritus—Sorafenib—liver cancer	0.00358	0.00419	CcSEcCtD
Travoprost—Diarrhoea—Sorafenib—liver cancer	0.00346	0.00406	CcSEcCtD
Travoprost—Dizziness—Sorafenib—liver cancer	0.00334	0.00392	CcSEcCtD
Travoprost—Influenza—Epirubicin—liver cancer	0.00328	0.00385	CcSEcCtD
Travoprost—Asthma—Epirubicin—liver cancer	0.00328	0.00385	CcSEcCtD
Travoprost—Angina pectoris—Epirubicin—liver cancer	0.0032	0.00375	CcSEcCtD
Travoprost—Rash—Sorafenib—liver cancer	0.00319	0.00374	CcSEcCtD
Travoprost—Dermatitis—Sorafenib—liver cancer	0.00318	0.00373	CcSEcCtD
Travoprost—Headache—Sorafenib—liver cancer	0.00317	0.00371	CcSEcCtD
Travoprost—Bronchitis—Epirubicin—liver cancer	0.00316	0.0037	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—TRIO—liver cancer	0.00311	0.0285	CbGpPWpGaD
Travoprost—Dysuria—Epirubicin—liver cancer	0.00307	0.0036	CcSEcCtD
Travoprost—Asthma—Doxorubicin—liver cancer	0.00304	0.00356	CcSEcCtD
Travoprost—Influenza—Doxorubicin—liver cancer	0.00304	0.00356	CcSEcCtD
Travoprost—Nausea—Sorafenib—liver cancer	0.003	0.00352	CcSEcCtD
Travoprost—Angina pectoris—Doxorubicin—liver cancer	0.00296	0.00347	CcSEcCtD
Travoprost—Infestation NOS—Epirubicin—liver cancer	0.00293	0.00343	CcSEcCtD
Travoprost—Infestation—Epirubicin—liver cancer	0.00293	0.00343	CcSEcCtD
Travoprost—Bronchitis—Doxorubicin—liver cancer	0.00292	0.00343	CcSEcCtD
Travoprost—Conjunctivitis—Epirubicin—liver cancer	0.00285	0.00334	CcSEcCtD
Travoprost—Urinary tract infection—Epirubicin—liver cancer	0.00285	0.00334	CcSEcCtD
Travoprost—Dysuria—Doxorubicin—liver cancer	0.00284	0.00333	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.00279	0.0255	CbGpPWpGaD
Travoprost—Sinusitis—Epirubicin—liver cancer	0.00275	0.00322	CcSEcCtD
Travoprost—Infestation NOS—Doxorubicin—liver cancer	0.00271	0.00318	CcSEcCtD
Travoprost—Infestation—Doxorubicin—liver cancer	0.00271	0.00318	CcSEcCtD
Travoprost—Bradycardia—Epirubicin—liver cancer	0.00268	0.00314	CcSEcCtD
Travoprost—Rhinitis—Epirubicin—liver cancer	0.00264	0.00309	CcSEcCtD
Travoprost—Conjunctivitis—Doxorubicin—liver cancer	0.00263	0.00309	CcSEcCtD
Travoprost—Urinary tract infection—Doxorubicin—liver cancer	0.00263	0.00309	CcSEcCtD
Travoprost—Pharyngitis—Epirubicin—liver cancer	0.00261	0.00306	CcSEcCtD
Travoprost—Urinary tract disorder—Epirubicin—liver cancer	0.0026	0.00304	CcSEcCtD
Travoprost—Connective tissue disorder—Epirubicin—liver cancer	0.00258	0.00303	CcSEcCtD
Travoprost—Urethral disorder—Epirubicin—liver cancer	0.00258	0.00302	CcSEcCtD
Travoprost—Sinusitis—Doxorubicin—liver cancer	0.00254	0.00298	CcSEcCtD
Travoprost—Visual impairment—Epirubicin—liver cancer	0.00253	0.00297	CcSEcCtD
Travoprost—Bradycardia—Doxorubicin—liver cancer	0.00248	0.0029	CcSEcCtD
Travoprost—Eye disorder—Epirubicin—liver cancer	0.00246	0.00288	CcSEcCtD
Travoprost—Tinnitus—Epirubicin—liver cancer	0.00245	0.00287	CcSEcCtD
Travoprost—Cardiac disorder—Epirubicin—liver cancer	0.00244	0.00286	CcSEcCtD
Travoprost—Rhinitis—Doxorubicin—liver cancer	0.00244	0.00286	CcSEcCtD
Travoprost—Pharyngitis—Doxorubicin—liver cancer	0.00241	0.00283	CcSEcCtD
Travoprost—Urinary tract disorder—Doxorubicin—liver cancer	0.0024	0.00282	CcSEcCtD
Travoprost—Connective tissue disorder—Doxorubicin—liver cancer	0.00239	0.0028	CcSEcCtD
Travoprost—Angiopathy—Epirubicin—liver cancer	0.00238	0.0028	CcSEcCtD
Travoprost—Urethral disorder—Doxorubicin—liver cancer	0.00238	0.0028	CcSEcCtD
Travoprost—Immune system disorder—Epirubicin—liver cancer	0.00237	0.00278	CcSEcCtD
Travoprost—Mediastinal disorder—Epirubicin—liver cancer	0.00237	0.00278	CcSEcCtD
Travoprost—Visual impairment—Doxorubicin—liver cancer	0.00234	0.00275	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00231	0.0211	CbGpPWpGaD
Travoprost—Mental disorder—Epirubicin—liver cancer	0.0023	0.0027	CcSEcCtD
Travoprost—Erythema—Epirubicin—liver cancer	0.00229	0.00268	CcSEcCtD
Travoprost—Eye disorder—Doxorubicin—liver cancer	0.00227	0.00267	CcSEcCtD
Travoprost—Tinnitus—Doxorubicin—liver cancer	0.00227	0.00266	CcSEcCtD
Travoprost—Cardiac disorder—Doxorubicin—liver cancer	0.00226	0.00265	CcSEcCtD
Travoprost—Dysgeusia—Epirubicin—liver cancer	0.00224	0.00263	CcSEcCtD
Travoprost—Back pain—Epirubicin—liver cancer	0.00221	0.0026	CcSEcCtD
Travoprost—Angiopathy—Doxorubicin—liver cancer	0.00221	0.00259	CcSEcCtD
Travoprost—Immune system disorder—Doxorubicin—liver cancer	0.0022	0.00258	CcSEcCtD
Travoprost—Mediastinal disorder—Doxorubicin—liver cancer	0.00219	0.00257	CcSEcCtD
Travoprost—Vision blurred—Epirubicin—liver cancer	0.00216	0.00253	CcSEcCtD
Travoprost—Mental disorder—Doxorubicin—liver cancer	0.00213	0.0025	CcSEcCtD
Travoprost—Ill-defined disorder—Epirubicin—liver cancer	0.00212	0.00249	CcSEcCtD
Travoprost—Erythema—Doxorubicin—liver cancer	0.00212	0.00248	CcSEcCtD
Travoprost—Dysgeusia—Doxorubicin—liver cancer	0.00207	0.00243	CcSEcCtD
Travoprost—Malaise—Epirubicin—liver cancer	0.00206	0.00242	CcSEcCtD
Travoprost—Vertigo—Epirubicin—liver cancer	0.00206	0.00241	CcSEcCtD
Travoprost—Back pain—Doxorubicin—liver cancer	0.00205	0.0024	CcSEcCtD
Travoprost—Palpitations—Epirubicin—liver cancer	0.00202	0.00237	CcSEcCtD
Travoprost—Cough—Epirubicin—liver cancer	0.002	0.00234	CcSEcCtD
Travoprost—Vision blurred—Doxorubicin—liver cancer	0.002	0.00234	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00198	0.0181	CbGpPWpGaD
Travoprost—Hypertension—Epirubicin—liver cancer	0.00198	0.00232	CcSEcCtD
Travoprost—Ill-defined disorder—Doxorubicin—liver cancer	0.00196	0.0023	CcSEcCtD
Travoprost—Arthralgia—Epirubicin—liver cancer	0.00195	0.00228	CcSEcCtD
Travoprost—Myalgia—Epirubicin—liver cancer	0.00195	0.00228	CcSEcCtD
Travoprost—Chest pain—Epirubicin—liver cancer	0.00195	0.00228	CcSEcCtD
Travoprost—Anxiety—Epirubicin—liver cancer	0.00194	0.00228	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00193	0.00227	CcSEcCtD
Travoprost—Discomfort—Epirubicin—liver cancer	0.00192	0.00226	CcSEcCtD
Travoprost—Malaise—Doxorubicin—liver cancer	0.00191	0.00224	CcSEcCtD
Travoprost—Dry mouth—Epirubicin—liver cancer	0.00191	0.00223	CcSEcCtD
Travoprost—Vertigo—Doxorubicin—liver cancer	0.0019	0.00223	CcSEcCtD
Travoprost—Palpitations—Doxorubicin—liver cancer	0.00187	0.00219	CcSEcCtD
Travoprost—Oedema—Epirubicin—liver cancer	0.00187	0.00219	CcSEcCtD
Travoprost—Infection—Epirubicin—liver cancer	0.00186	0.00218	CcSEcCtD
Travoprost—Cough—Doxorubicin—liver cancer	0.00185	0.00217	CcSEcCtD
Travoprost—Nervous system disorder—Epirubicin—liver cancer	0.00183	0.00215	CcSEcCtD
Travoprost—Hypertension—Doxorubicin—liver cancer	0.00183	0.00214	CcSEcCtD
Travoprost—Tachycardia—Epirubicin—liver cancer	0.00182	0.00214	CcSEcCtD
Travoprost—Skin disorder—Epirubicin—liver cancer	0.00181	0.00213	CcSEcCtD
Travoprost—Arthralgia—Doxorubicin—liver cancer	0.0018	0.00211	CcSEcCtD
Travoprost—Chest pain—Doxorubicin—liver cancer	0.0018	0.00211	CcSEcCtD
Travoprost—Myalgia—Doxorubicin—liver cancer	0.0018	0.00211	CcSEcCtD
Travoprost—Anxiety—Doxorubicin—liver cancer	0.0018	0.00211	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00179	0.0021	CcSEcCtD
Travoprost—Discomfort—Doxorubicin—liver cancer	0.00178	0.00209	CcSEcCtD
Travoprost—Dry mouth—Doxorubicin—liver cancer	0.00176	0.00207	CcSEcCtD
Travoprost—Hypotension—Epirubicin—liver cancer	0.00175	0.00205	CcSEcCtD
Travoprost—Oedema—Doxorubicin—liver cancer	0.00173	0.00203	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—PRKCE—liver cancer	0.00172	0.0157	CbGpPWpGaD
Travoprost—Infection—Doxorubicin—liver cancer	0.00172	0.00201	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Epirubicin—liver cancer	0.0017	0.002	CcSEcCtD
Travoprost—Nervous system disorder—Doxorubicin—liver cancer	0.00169	0.00199	CcSEcCtD
Travoprost—Tachycardia—Doxorubicin—liver cancer	0.00169	0.00198	CcSEcCtD
Travoprost—Skin disorder—Doxorubicin—liver cancer	0.00168	0.00197	CcSEcCtD
Travoprost—Dyspnoea—Epirubicin—liver cancer	0.00167	0.00195	CcSEcCtD
Travoprost—Dyspepsia—Epirubicin—liver cancer	0.00164	0.00193	CcSEcCtD
Travoprost—Hypotension—Doxorubicin—liver cancer	0.00161	0.00189	CcSEcCtD
Travoprost—Gastrointestinal disorder—Epirubicin—liver cancer	0.00161	0.00189	CcSEcCtD
Travoprost—Fatigue—Epirubicin—liver cancer	0.00161	0.00189	CcSEcCtD
Travoprost—Pain—Epirubicin—liver cancer	0.0016	0.00187	CcSEcCtD
Travoprost—Constipation—Epirubicin—liver cancer	0.0016	0.00187	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00157	0.00185	CcSEcCtD
Travoprost—Dyspnoea—Doxorubicin—liver cancer	0.00154	0.00181	CcSEcCtD
Travoprost—Feeling abnormal—Epirubicin—liver cancer	0.00154	0.0018	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.00154	0.0141	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Epirubicin—liver cancer	0.00153	0.00179	CcSEcCtD
Travoprost—Dyspepsia—Doxorubicin—liver cancer	0.00152	0.00178	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CCR4—liver cancer	0.00151	0.0138	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00149	0.00175	CcSEcCtD
Travoprost—Fatigue—Doxorubicin—liver cancer	0.00149	0.00175	CcSEcCtD
Travoprost—Pain—Doxorubicin—liver cancer	0.00148	0.00173	CcSEcCtD
Travoprost—Constipation—Doxorubicin—liver cancer	0.00148	0.00173	CcSEcCtD
Travoprost—Abdominal pain—Epirubicin—liver cancer	0.00148	0.00173	CcSEcCtD
Travoprost—Feeling abnormal—Doxorubicin—liver cancer	0.00142	0.00167	CcSEcCtD
Travoprost—Gastrointestinal pain—Doxorubicin—liver cancer	0.00141	0.00166	CcSEcCtD
Travoprost—Hypersensitivity—Epirubicin—liver cancer	0.00138	0.00161	CcSEcCtD
Travoprost—Abdominal pain—Doxorubicin—liver cancer	0.00137	0.0016	CcSEcCtD
Travoprost—Asthenia—Epirubicin—liver cancer	0.00134	0.00157	CcSEcCtD
Travoprost—Pruritus—Epirubicin—liver cancer	0.00132	0.00155	CcSEcCtD
Travoprost—Diarrhoea—Epirubicin—liver cancer	0.00128	0.0015	CcSEcCtD
Travoprost—Hypersensitivity—Doxorubicin—liver cancer	0.00127	0.00149	CcSEcCtD
Travoprost—Asthenia—Doxorubicin—liver cancer	0.00124	0.00145	CcSEcCtD
Travoprost—Dizziness—Epirubicin—liver cancer	0.00123	0.00145	CcSEcCtD
Travoprost—Pruritus—Doxorubicin—liver cancer	0.00122	0.00143	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—F2—liver cancer	0.00119	0.0109	CbGpPWpGaD
Travoprost—Diarrhoea—Doxorubicin—liver cancer	0.00118	0.00139	CcSEcCtD
Travoprost—Rash—Epirubicin—liver cancer	0.00118	0.00138	CcSEcCtD
Travoprost—Dermatitis—Epirubicin—liver cancer	0.00118	0.00138	CcSEcCtD
Travoprost—Headache—Epirubicin—liver cancer	0.00117	0.00137	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CHN2—liver cancer	0.00115	0.0105	CbGpPWpGaD
Travoprost—Dizziness—Doxorubicin—liver cancer	0.00114	0.00134	CcSEcCtD
Travoprost—Nausea—Epirubicin—liver cancer	0.00111	0.0013	CcSEcCtD
Travoprost—Rash—Doxorubicin—liver cancer	0.00109	0.00128	CcSEcCtD
Travoprost—Dermatitis—Doxorubicin—liver cancer	0.00109	0.00128	CcSEcCtD
Travoprost—Headache—Doxorubicin—liver cancer	0.00108	0.00127	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.00107	0.00977	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IFT88—liver cancer	0.00105	0.0096	CbGpPWpGaD
Travoprost—Nausea—Doxorubicin—liver cancer	0.00103	0.0012	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—TRIO—liver cancer	0.000888	0.00812	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCR4—liver cancer	0.000851	0.00779	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—TRIO—liver cancer	0.000806	0.00738	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000802	0.00734	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000791	0.00724	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCR4—liver cancer	0.000773	0.00707	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SHC3—liver cancer	0.000643	0.00588	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—F2—liver cancer	0.000602	0.00551	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3CA—liver cancer	0.000534	0.00488	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000519	0.00475	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FST—liver cancer	0.000499	0.00457	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PRKCE—liver cancer	0.00049	0.00449	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000477	0.00437	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TRIO—liver cancer	0.000476	0.00436	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCR4—liver cancer	0.000457	0.00418	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PRKCE—liver cancer	0.000445	0.00407	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000442	0.00404	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CSF2—liver cancer	0.000434	0.00397	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000423	0.00387	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CSF2—liver cancer	0.000394	0.0036	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ADAM17—liver cancer	0.000361	0.0033	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—F2—liver cancer	0.00034	0.00311	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PSMA4—liver cancer	0.000339	0.00311	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PSMD10—liver cancer	0.000339	0.00311	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—liver cancer	0.000326	0.00298	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—F2—liver cancer	0.000309	0.00283	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—liver cancer	0.000296	0.00271	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CD—liver cancer	0.000286	0.00262	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRKCE—liver cancer	0.000263	0.00241	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CD—liver cancer	0.00026	0.00238	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CB—liver cancer	0.000249	0.00228	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IGF2—liver cancer	0.000249	0.00228	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CSF2—liver cancer	0.000233	0.00213	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RAF1—liver cancer	0.000232	0.00212	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—H2AFX—liver cancer	0.000229	0.0021	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL2—liver cancer	0.000229	0.0021	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CB—liver cancer	0.000227	0.00207	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL2—liver cancer	0.000208	0.0019	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TERT—liver cancer	0.000207	0.0019	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KDR—liver cancer	0.00019	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK14—liver cancer	0.000188	0.00172	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ESR1—liver cancer	0.000185	0.00169	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—F2—liver cancer	0.000182	0.00167	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APC—liver cancer	0.000175	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—liver cancer	0.000175	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BRAF—liver cancer	0.000164	0.0015	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CD—liver cancer	0.000154	0.00141	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CA—liver cancer	0.000152	0.00139	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SERPINE1—liver cancer	0.000152	0.00139	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—KRAS—liver cancer	0.00015	0.00138	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CA—liver cancer	0.000138	0.00126	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RAF1—liver cancer	0.000137	0.00125	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MTOR—liver cancer	0.000134	0.00122	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CB—liver cancer	0.000134	0.00122	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—HRAS—liver cancer	0.000128	0.00117	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1B—liver cancer	0.000126	0.00115	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—liver cancer	0.000124	0.00114	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASP3—liver cancer	0.000123	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL2—liver cancer	0.000123	0.00112	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—liver cancer	0.000122	0.00112	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCND1—liver cancer	0.00012	0.0011	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JUN—liver cancer	0.00012	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTNNB1—liver cancer	0.000119	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP9—liver cancer	0.000116	0.00106	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1A—liver cancer	0.000116	0.00106	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK8—liver cancer	0.000113	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—liver cancer	0.000113	0.00103	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFA—liver cancer	0.000104	0.000956	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT3—liver cancer	0.000103	0.000947	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MYC—liver cancer	9.61e-05	0.00088	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFB1—liver cancer	9.59e-05	0.000877	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KRAS—liver cancer	8.88e-05	0.000813	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CA—liver cancer	8.16e-05	0.000747	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TP53—liver cancer	7.89e-05	0.000722	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HRAS—liver cancer	7.55e-05	0.000691	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—liver cancer	7.22e-05	0.000661	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—liver cancer	6.66e-05	0.00061	CbGpPWpGaD
